{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:28:08Z","timestamp":1786663688675,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Patients with peritoneal dialysis (PD) often develop exit-site infections (ESI) caused by non\n                      <jats:italic>tuberculous mycobacteria<\/jats:italic>\n                      . Antimicrobial therapy, including intravenous amikacin (AMK), is combined with PD catheter removal to control the source of infection. However, the efficiency of AMK removal using PD remains unclear. In this report, we describe AMK pharmacokinetics before and after PD catheter removal in a patient diagnosed with\n                      <jats:italic>Mycobacterium abscessus<\/jats:italic>\n                      from ESI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 73-year-old female PD patient weighing 42.4\u00a0kg who received intravenous AMK\u2009+\u2009clarithromycin\u2009+\u2009imipenem\/cilastatin for\n                      <jats:italic>Mycobacterium abscessus<\/jats:italic>\n                      ESI on day 1 under therapeutic drug monitoring. During hospitalization, the patient underwent a typical PD regimen including nocturnal continuous ambulatory PD with Reguneal HCa 1.5\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (1.5% glucose) 1.5\u00a0L (2-hour storage) + Reguneal HCa 1.5\n                      <jats:sup>\u00ae<\/jats:sup>\n                      1.5\u00a0L or Extraneal\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (7.5% icodextrin) 1.5\u00a0L (11.5-hour storage). Dosing schedule of AMK was 200\u00a0mg every 48\u00a0h to maintain an AMK trough concentration around 10\u00a0\u00b5g\/mL. On day 14, the PD catheter was removed and reinserted on the contralateral side for source control of the infection site and PD was discontinued until day 20. The elimination rate constant (Ke) of AMK was 0.027\u00a0h\n                      <jats:sup>\u2212\u20091<\/jats:sup>\n                      obtained from peak concentration (C\n                      <jats:sub>peak<\/jats:sub>\n                      ) of 16.3\u00a0\u00b5g\/mL on day 1 and trough concentration (C\n                      <jats:sub>trough<\/jats:sub>\n                      ) of 4.5\u00a0\u00b5g\/mL on day 3. In contrast, Ke was 0.020\u00a0h\n                      <jats:sup>\u2212\u20091<\/jats:sup>\n                      calculated from both C\n                      <jats:sub>peak<\/jats:sub>\n                      of 22.2\u00a0\u00b5g\/mL on day 9 and C\n                      <jats:sub>trough<\/jats:sub>\n                      of 8.4\u00a0\u00b5g\/mL on day 11, as well as C\n                      <jats:sub>peak<\/jats:sub>\n                      of 23.8\u00a0\u00b5g\/mL on day 17 and C\n                      <jats:sub>trough<\/jats:sub>\n                      was 9.3\u00a0\u00b5g\/mL on day 19. Combination antibiotic therapy was completed due to clinical improvement on day 27. Post-treatment, clofazimine and clarithromycin were administered orally, and the patient was discharged on day 32.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The effect of PD on AMK concentration was limited during therapeutic drug monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-026-00593-z","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:24:15Z","timestamp":1780928655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic drug monitoring of intravenous amikacin during peritoneal dialysis for Mycobacterium abscessus exit-site infection: a case report"],"prefix":"10.1186","volume":"12","author":[{"given":"Yuki","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ei","family":"Kusahana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Hosonuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeaki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"593_CR1","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s40620-020-00787-0","volume":"33","author":"SCW Tang","year":"2020","unstructured":"Tang SCW, Lai KN. Peritoneal dialysis: the ideal bridge from conservative therapy to kidney transplant. J Nephrol. 2020;33:1189\u201394.","journal-title":"J Nephrol"},{"key":"593_CR2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41581-022-00623-7","volume":"18","author":"AK Bello","year":"2022","unstructured":"Bello AK, Okpechi IG, Osman MA, Cho Y, Cullis B, Htay H, et al. Epidemiology of peritoneal dialysis outcomes. Nat Rev Nephrol. 2022;18:779\u201393.","journal-title":"Nat Rev Nephrol"},{"key":"593_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/08968608231172740","volume":"43","author":"KM Chow","year":"2023","unstructured":"Chow KM, Li PKT, Cho Y, Abu-Alfa A, Bavanandan S, Brown EA, et al. ISPD catheter-related infection recommendations: 2023 update. Perit Dial Int. 2023;43:201\u201319.","journal-title":"Perit Dial Int"},{"key":"593_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/08968608221080586","volume":"42","author":"PK-T Li","year":"2022","unstructured":"Li PK-T, Chow KM, Cho Y, Fan S, Figueiredo AE, Harris T, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int. 2022;42:110\u201353.","journal-title":"Perit Dial Int"},{"key":"593_CR5","doi-asserted-by":"crossref","unstructured":"Shulha JA, Escalante P, Wilson JW. Pharmacotherapy approaches in nontuberculous mycobacteria infections. Mayo Clin Proc. 2019;94(8):1567-1581.","DOI":"10.1016\/j.mayocp.2018.12.011"},{"key":"593_CR6","doi-asserted-by":"publisher","first-page":"100244","DOI":"10.1016\/j.jctube.2021.100244","volume":"24","author":"KM Pennington","year":"2021","unstructured":"Pennington KM, Vu A, Challener D, Rivera CG, Shweta FNU, Zeuli JD, et al. Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease. J Clin Tuberc Other Mycobact Dis. 2021;24:100244.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"593_CR7","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12882-024-03841-2","volume":"25","author":"N Kadota","year":"2024","unstructured":"Kadota N, Ishikawa K, Kubono Y, Konishi K, Fujimaru T, Ito Y, et al. Systematic literature review of the diagnosis, prognosis, and treatment of peritoneal dialysis-related infection caused by nontuberculous mycobacteria. BMC Nephrol. 2024;25:432.","journal-title":"BMC Nephrol"},{"key":"593_CR8","unstructured":"Clinical practice guidelines for therapeutic drug monitoring of antimicrobial agents. 2022. https:\/\/www.chemotherapy.or.jp\/uploads\/files\/guideline\/tdm2022.pdf. Accessed 20 Jan 2026."},{"key":"593_CR9","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020;46:1127\u201353.","journal-title":"Intensive Care Med"},{"key":"593_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.18773\/austprescr.2025.038","volume":"48","author":"H Moore","year":"2025","unstructured":"Moore H, Yeoh D, Hughes C, Raby E, Sandaradura I. Aminoglycosides: an update on indications, dosing and monitoring. Aust Prescr. 2025;48:133\u20138.","journal-title":"Aust Prescr"},{"key":"593_CR11","first-page":"129","volume-title":"Basic clinical pharmacokinetics. Japanese translation. Higuchi S, translator","author":"ME Winter","year":"2013","unstructured":"Winter ME. Basic clinical pharmacokinetics. Japanese translation. Higuchi S, translator. Tokyo: Jiho; 2013. pp. 129\u201371."},{"key":"593_CR12","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/phar.2193","volume":"38","author":"CM Bland","year":"2018","unstructured":"Bland CM, Pai MP, Lodise TP. Reappraisal of contemporary pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing. Pharmacotherapy. 2018;38:1229\u201338.","journal-title":"Pharmacotherapy"},{"key":"593_CR13","doi-asserted-by":"publisher","first-page":"1394220","DOI":"10.3389\/fmicb.2024.1394220","volume":"15","author":"LE Conyers","year":"2024","unstructured":"Conyers LE, Saunders BM. Treatment for non-tuberculous mycobacteria: challenges and prospects. Front Microbiol. 2024;15:1394220.","journal-title":"Front Microbiol"},{"key":"593_CR14","doi-asserted-by":"publisher","first-page":"e01206","DOI":"10.1128\/AAC.01206-17","volume":"61","author":"JG Pasipanodya","year":"2017","unstructured":"Pasipanodya JG, Ogbonna D, Ferro BE, Magombedze G, Srivastava S, Deshpande D, et al. Systematic review and meta-analyses of the effect of chemotherapy on pulmonary mycobacterium abscessus outcomes and disease recurrence. Antimicrob Agents Chemother. 2017;61:e01206\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"593_CR15","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/ccr3.2774","volume":"8","author":"S Kojya","year":"2020","unstructured":"Kojya S, Shiohira H, Sunagawa Y, Tsuneyoshi S, Kohagura K, Ohya Y, et al. Therapeutic drug monitoring in peritoneal dialysis: A case of nontuberculous mycobacterium catheter-related infection treated with amikacin. Clin Case Rep. 2020;8:995\u20138.","journal-title":"Clin Case Rep"},{"key":"593_CR16","unstructured":"Amikacin interview form. https:\/\/www.nichiiko.co.jp\/medicine\/file\/55280\/blending\/55280_blending.pdf. Accessed 20 Jan 2026."},{"key":"593_CR17","first-page":"122","volume":"24","author":"L Regeur","year":"1977","unstructured":"Regeur L, Colding H, Jensen H, Kampmann JP. Pharmacokinetics of amikacin during hemo and peritoneal dialysis. Dan Med Bull. 1977;24:122.","journal-title":"Dan Med Bull"},{"key":"593_CR18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1128\/AAC.10.3.464","volume":"10","author":"T Madhavan","year":"1976","unstructured":"Madhavan T, Yaremchuk K, Levin N, Pohlod D, Burch K, Fisher E, et al. Effect of renal failure and dialysis on the serum concentration of the aminoglycoside amikacin. Antimicrob Agents Chemother. 1976;10:464\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"593_CR19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","volume":"71","author":"CL Daley","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Clin Infect Dis. 2020;71:905\u201313.","journal-title":"Clin Infect Dis"},{"key":"593_CR20","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"593_CR21","first-page":"31","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341.","journal-title":"Nephron"},{"key":"593_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1128\/AAC.32.2.236","volume":"32","author":"BD Smeltzer","year":"1988","unstructured":"Smeltzer BD, Schwartzman MS, Bertino JS. Amikacin pharmacokinetics during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother. 1988;32:236\u201340.","journal-title":"Antimicrob Agents Chemother"},{"key":"593_CR23","doi-asserted-by":"publisher","first-page":"e0167921","DOI":"10.1128\/aac.01679-21","volume":"66","author":"A Farkas","year":"2022","unstructured":"Farkas A, Oikonomou K, Ghanbar M, Villasurda P, Varghese J, Lipman J, et al. Population pharmacokinetics of intraperitoneal gentamicin and the impact of varying dwell times on pharmacodynamic target attainment in patients with acute peritonitis undergoing peritoneal dialysis. Antimicrob Agents Chemother. 2022;66:e0167921.","journal-title":"Antimicrob Agents Chemother"},{"key":"593_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/089686088700700306","volume":"7","author":"ZJT Karl","year":"1987","unstructured":"Karl ZJT, Khanna ONR, Leonor BFP, Ryan P, Moore HL, Nielsen MP. Peritoneal equilibration test. Perit Dial Int. 1987;7:138\u201348.","journal-title":"Perit Dial Int"},{"key":"593_CR25","doi-asserted-by":"publisher","first-page":"30109","DOI":"10.1038\/s41598-024-81934-6","volume":"14","author":"T Sakurada","year":"2024","unstructured":"Sakurada T, Zhao J, Tu C, Bieber B, Cheetham M, Pisoni RL, et al. Effects of initial peritoneal dialysis prescription on clinical outcomes in Japanese peritoneal dialysis patients: a cohort study. Sci Rep. 2024;14:30109.","journal-title":"Sci Rep"},{"key":"593_CR26","doi-asserted-by":"publisher","first-page":"119963","DOI":"10.1016\/j.cca.2024.119963","volume":"565","author":"J Kim","year":"2025","unstructured":"Kim J, Rim JH, Jang J, Jang H, Lim JB. Comparative assessment of trough and peak levels and AUC24 for amikacin in nontuberculous mycobacterial infection. Clin Chim Acta. 2025;565:119963.","journal-title":"Clin Chim Acta"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-026-00593-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00593-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00593-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:57:51Z","timestamp":1786661871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-026-00593-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["593"],"URL":"https:\/\/doi.org\/10.1186\/s40780-026-00593-z","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required. Written informed consent was obtained from the patient.","order":1,"name":"Ethics","label":"<b>Ethics approval and consent to participate<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for the publication of this case report was obtained from the patient.","order":2,"name":"Ethics","label":"<b>Consent for publication<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"<b>Competing interests<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"72"}}